| Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention Z Younossi, QM Anstee, M Marietti, T Hardy, L Henry, M Eslam, J George, ... Nature reviews Gastroenterology & hepatology 15 (1), 11-20, 2018 | 5296 | 2018 |
| A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement M Eslam, PN Newsome, SK Sarin, QM Anstee, G Targher, ... Journal of hepatology 73 (1), 202-209, 2020 | 3842 | 2020 |
| MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease M Eslam, AJ Sanyal, J George, A Sanyal, B Neuschwander-Tetri, ... Gastroenterology 158 (7), 1999-2014. e1, 2020 | 3043 | 2020 |
| Genetics and epigenetics of NAFLD and NASH: Clinical impact M Eslam, L Valenti, S Romeo Journal of hepatology 68 (2), 268-279, 2018 | 1018 | 2018 |
| Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study E Vilar-Gomez, L Calzadilla-Bertot, VWS Wong, M Castellanos, ... Gastroenterology 155 (2), 443-457. e17, 2018 | 759 | 2018 |
| The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease M Eslam, SK Sarin, VWS Wong, JG Fan, T Kawaguchi, SH Ahn, ... Hepatology international 14, 889-919, 2020 | 719 | 2020 |
| Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission SK Sarin, M Kumar, M Eslam, J George, M Al Mahtab, SMF Akbar, J Jia, ... The lancet Gastroenterology & hepatology 5 (2), 167-228, 2020 | 528 | 2020 |
| MAFLD identifies patients with significant hepatic fibrosis better than NAFLD S Yamamura, M Eslam, T Kawaguchi, T Tsutsumi, D Nakano, ... Liver International 40 (12), 3018-3030, 2020 | 402 | 2020 |
| The changing epidemiology of liver diseases in the Asia–Pacific region MCS Wong, JLW Huang, J George, J Huang, C Leung, M Eslam, ... Nature reviews Gastroenterology & hepatology 16 (1), 57-73, 2019 | 319 | 2019 |
| Lean NAFLD: a distinct entity shaped by differential metabolic adaptation F Chen, S Esmaili, GB Rogers, E Bugianesi, S Petta, G Marchesini, ... Hepatology 71 (4), 1213-1227, 2020 | 315 | 2020 |
| Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology M Eslam, J George Nature reviews Gastroenterology & hepatology 17 (1), 40-52, 2020 | 301 | 2020 |
| ADAPT: an algorithm incorporating PRO‐C3 accurately identifies patients with NAFLD and advanced fibrosis SJ Daniels, DJ Leeming, M Eslam, AM Hashem, MJ Nielsen, A Krag, ... Hepatology 69 (3), 1075-1086, 2019 | 242 | 2019 |
| Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement M Eslam, N Alkhouri, P Vajro, U Baumann, R Weiss, P Socha, C Marcus, ... The Lancet Gastroenterology & Hepatology 6 (10), 864-873, 2021 | 227 | 2021 |
| Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores G Targher, A Mantovani, CD Byrne, XB Wang, HD Yan, QF Sun, KH Pan, ... Gut 69 (8), 1545-1547, 2020 | 222 | 2020 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 214 | 2022 |
| Redefining fatty liver disease: an international patient perspective G Shiha, M Korenjak, W Eskridge, T Casanovas, P Velez-Moller, ... The lancet Gastroenterology & hepatology 6 (1), 73-79, 2021 | 198 | 2021 |
| Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals KE Chan, TJL Koh, ASP Tang, J Quek, JN Yong, P Tay, DJH Tan, WH Lim, ... The Journal of Clinical Endocrinology & Metabolism 107 (9), 2691-2700, 2022 | 193 | 2022 |
| Patients with diabetes are at higher risk for severe illness from COVID-19 G Targher, A Mantovani, XB Wang, HD Yan, QF Sun, KH Pan, CD Byrne, ... Diabetes & metabolism 46 (4), 335, 2020 | 190 | 2020 |
| Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease M Eslam, AM Hashem, R Leung, M Romero-Gomez, T Berg, GJ Dore, ... Nature communications 6 (1), 6422, 2015 | 186 | 2015 |
| Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? R Younes, O Govaere, S Petta, L Miele, D Tiniakos, A Burt, E David, ... Gut 71 (2), 382-390, 2022 | 173 | 2022 |